Duloxetine in the management of elderly patients with major depressive disorder: An analysis of published data

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 5, 2009, Pages 847-860

  Mancini, M ^a   Gianni, W ^a,b   Rossi, A ^a   Amore, M ^a,c  

^a Eli Lilly Italia SpA   (Italy)

^b INRCA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Depression; Duloxetine; Elderly

Indexed keywords

DULOXETINE; ESCITALOPRAM; PLACEBO;

AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; BACKACHE; BLOATING; BLOOD PRESSURE; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HEALTH STATUS; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; MAJOR DEPRESSION; MANIA; MINI MENTAL STATE EXAMINATION; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; QUALITY OF LIFE; REMISSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

AGE FACTORS; AGED; ANIMALS; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DISEASE MANAGEMENT; HUMANS; THIOPHENES;

EID: 67649588310     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902806431     Document Type: Review

References (57)

1. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60(Suppl 20):9-15 (Pubitemid 29468384)
2. Lee JS, Potter GG, Wagner HR, et al. Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr 2007;19:125-135 (Pubitemid 44953331)
3. Rovner BW, German PS, Brant LJ, et al. Depression and mortality in nursing homes. JAMA 1991;265:993-996
4. Greden JF. Unmet need: what justifies the search for a new antidepressant? J Clin Psychiatry 2002;63(Suppl 2):3-7
5. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005;27:1126-1143 (Pubitemid 41393910)
6. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008;42:22-34 (Pubitemid 47570043)
7. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-132
8. Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212-219 (Pubitemid 44371559)
9. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909 •• This article reports the results of the first study, specifically designed for elderly patients with recurrent MDD that compares the effects of duloxetine 60 mg/day vs placebo on cognition, depression and pain (Pubitemid 46972905)
10. Wise TN, Wiltse CG, Iosifescu DV, et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract 2007;61:1283-1293 •• This study comprehensively analyzes the safety and tolerability of duloxetine in elderly patients with MDD and medical comorbidities (Pubitemid 47052377)
11. Wohlreich MM, Sullivan MD, Mallinckrodt CH, et al. Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis. Psychosomatics 2009. In press •• This study describes the effects of duloxetine in elderly patients with MDD and comorbid arthritis
12. Russell JM, Raskin J, Wiltse CG, et al. Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms. Psychiatry 2007;4:33-45 • This study reports the effects of duloxetine in elderly patients with MDD and concurrent anxiety symptoms
13. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008;28:32 •• This article compares the safety and tolerability profile of duloxetine 60 mg/day vs placebo in the elderly patients with MDD
14. Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005;13:227-235 •• This article combines the results of six registration trials investigating the short-term effects of duloxetine vs placebo in MDD patients older than 55 (Pubitemid 41031091)
15. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr 2004;4:11 •• This article provides data on the long-term effect of duloxetine use in elderly patients with MDD (Pubitemid 44811706)
16. Karp JF, Whyte EM, Lenze EJ, et al. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability. J Clin Psychiatry 2008;69:457-463 •• This article evaluates the results of duloxetine use, up to 120 mg/day, in elderly patients with MDD who fail to respond to previous treatment with escitalopram (Pubitemid 351549400)
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33 (Pubitemid 29001829)
19. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch De Psychologie 1941;28:286-340
20. Wechsler D. Wechsler Adult Intelligence Scale. Third edition. San Antonio, TX: Psychological Corporation, 1997
21. Neisser U. Visual search. Sci Am 1964;210:94-102
22. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49
23. Deloach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102-106 (Pubitemid 28040099)
24. Leon AC, Shear MK, Portera L, et al. Assessing impairment in patients with panic disorder: the sheehan disability scale. Soc Psychiatry Psychiatr Epidemiol 1992;27:78-82
25. Ware J, Kosinski M, Keller S. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Centre, 1997
26. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40 (Pubitemid 30046590)
27. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100 (Pubitemid 17115352)
28. Raskin J, Xu JY, Kajdasz DK. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. Int Psychogeriatr 2008;20:309-327 • This article analyzes symptomatic response through time when using duloxetine in the elderly patients with MDD (Pubitemid 351230223)
29. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-455 (Pubitemid 46740340)
30. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25:132-140 (Pubitemid 40395091)
31. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-416 (Pubitemid 46333388)
32. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-470 (Pubitemid 39626894)
33. Dombrovski AY, Mulsant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 2007;103(1-3):77-82 (Pubitemid 47445755)
34. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006;67:1754-1759 (Pubitemid 44955157)
35. Demyttenaere K, Jaspers L. Bupropion and SSRI-induced side effects. Psychopharmacol 2008;22:792-804
36. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997;46:191-217 (Pubitemid 28165944)
37. Reynolds CF 3rd, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006;354:1130-1138
38. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002;5:147-151
39. Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract 2004;10:196-199 (Pubitemid 38669730)
40. Wongpakaran N, van Reekum R, Wongpakaran T, et al. Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry 2007;6:7 (Pubitemid 46404374)
41. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997:7(Suppl 1):49-55
42. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effectson social functioning. J Psychopharmacol 1997;11(Suppl 4):17-23 (Pubitemid 27526052)
43. Kennedy SH, Evans KR, Krueger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001;158:899-905 (Pubitemid 32547619)
44. Damsa C, Bumb A, Bianchi-Demicheli F, et al. 'Dopamine-dependent' side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004;65:1064-1068
45. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile and clinical results in depression. Curr Pharm Des 2005;11:1475-1493 (Pubitemid 40691447)
46. Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 2008;69:95-105 (Pubitemid 351282002)
47. Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006;8:269-278 (Pubitemid 44526504)
48. Roose SP. Treatment of depression in patients with heart disease. Biol Psychiatry 2003;54:262-268 (Pubitemid 37267856)
49. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. J Clin Psychiatry 1998;59(Suppl 15):13-18 (Pubitemid 28467473)
50. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008;16:558-567
51. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004;19:754-762 (Pubitemid 39149252)
52. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002;288:1403-1409 (Pubitemid 35025915)
53. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006;1:CD003491
54. Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. Br J Psychiatry 2006;188:410-415
55. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002;106:168-170
56. McManus P, Mant A, Mitchell P, et al. Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust NZ J Psychiatry 2004;38:450-454 (Pubitemid 39029053)
57. Wee R. Review: tricyclic related drugs, but not classical tricyclics, are a tolerable alternative to SSRIs in older people with depression. Evid Based Ment Health 2005;8:22